ESSEX BIO-TECH's subsidiary has been approved for the commercialization of multi-dose sodium dequalinium eye drops in China

Zhitong
2025.07.23 12:47
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, ESSEX BIO-TECH announced that its indirectly wholly-owned subsidiary, Zhuhai ESSEX Bio-Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration to register and commercialize multi-dose Diquafosol Sodium Eye Drops in mainland China (approved product). The approved product is a multi-dose eye drop containing 3% (5ml: 150mg) Diquafosol Sodium, suitable for the treatment of dry eye syndrome (such as conjunctival epithelial damage and tear abnormalities)

According to the Zhitong Finance APP, ESSEX BIO-TECH (01061) announced that its indirectly wholly-owned subsidiary, Zhuhai ESSEX BIO-TECH Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration to register and commercialize multi-dose sodium hyaluronate eye drops in mainland China (approved product).

The approved product is a multi-dose eye drop solution containing 3% (5ml: 150mg) sodium hyaluronate, suitable for the treatment of dry eye syndrome (such as conjunctival epithelial damage and tear abnormalities)

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer